focus -WSS

focus

author：Wikipedia 2025-09-27 10:02:11 - browse：55

Erik Tokat -- biotech JPM coverage from STAT — Eric Tokat is co-president of investment banking at Centerview Partners. Courtesy Centerview Partners

SAN FRANCISCO — Eric Tokat, biotech’s most prolific dealmaker, believes 2024 will be another strong year for acquisitions, driven by Big Pharma’s need to restock pipelines with medicines that can generate sales in the coming years.

That’s not idle speculation. It’s perhaps as close to a guarantee one can get in biotech. Last year, Tokat’s advisory firm, Centerview Partners, was involved in 19 of the 23 biotech transactions valued at $1 billion or more. Two more acquisitions of Centerview clients — Harpoon Therapeutics and Ambrx Biopharma — were announced Monday morning.

“I’m not sure if we’re going to have 23 deals or 25 deals, but I think it’s going to be a good year,” said Tokat, speaking to STAT over coffee on the sidelines of the J.P. Morgan Healthcare Conference.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

hotspot

WSS

Pregnancy discrimination could be enabled by AI

RSV injection headlines need to be accurate for good uptake

What PEPFAR has meant on the ground in Ukraine

The biotech scorecard for Q4: 16 stock

STAT Health News: mRNA flu shots, Purdue SCOTUS case, etc

Supreme Court wrestles with OxyContin maker's bankruptcy deal

explore

focus

leisure time

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

What will Novo Nordisk's VC do with its influx of cash?

The high cost of giving birth even with insurance

The United States is paying nearly triple for new Covid vaccines

The cancer drug shortage isn’t new — and neither are the solutions

Congenital heart disease patients face new threat of heart failure

Bright Health sells Medicare Advantage business to Molina

CDC picks Alphabet's Verily for wasterwater surveillance contract

Duchenne breakthrough therapy leaves behind pioneering families

Some top drug companies are starting to take action on climate

leisure time

AI models in health care face new federal disclosure requirements

Experts study whether long Covid risk adds up with each reinfection

Pfizer plans to depart BIO

STAT Health News: mRNA flu shots, Purdue SCOTUS case, etc

Health insurers' Q3 question: how much care are people getting?

What will Novo Nordisk's VC do with its influx of cash?

focus

hotspot

leisure time

hotspot